Nexalin Technology Validates Neurostimulation Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy NXL?
Nexalin Technology highlighted Nexalin's peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently, Nexalin is advancing its "mood-military-memory" clinical business plan with the FDA by publishing and submitting extensive clinical data. "Across multiple independent studies, we are not just observing that patients feel better-we are seeing measurable changes in how the brain functions," said Mark White, CEO of Nexalin Technology. "That distinction matters. Nexalin is a powerful whole-brain neurostimulation medical device that evidence indicates can penetrate deep in the brain to dramatically increase positive treatment response. Nexalin is not another battery-operated internet device sold to consumers. Our DIFS technology is designed to regulate abnormal neural signaling and normalize disrupted brain networks, and we have objective imaging data to support that mechanism."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NXL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NXL
About NXL
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nexalin Advances HALO Clarity Clinical Trial for Insomnia Treatment
- Clinical Trial Launch: Nexalin Technology is advancing its HALO Clarity program by initiating a pivotal clinical trial aimed at supporting a de novo submission to the U.S. FDA for moderate to severe insomnia treatment, which is expected to provide a competitive edge in the multi-billion-dollar insomnia market.
- Technological Innovation: The company positions its non-drug Deep Intracranial Frequency Stimulation (DIFS) technology as a potential alternative to address insomnia affecting approximately 30 million adults in the U.S., particularly as many patients express dissatisfaction with current treatment options due to concerns about dependency and tolerability.
- Trial Design: The HALO Clarity study is a randomized, triple-blinded, sham-controlled trial designed to enroll at least 150 adults, utilizing a fully decentralized model that allows participants to complete treatments and assessments remotely through Nexalin's NeuroCare virtual clinic, thereby broadening patient access.
- Strategic Implications: This trial builds on previously published clinical data demonstrating significant improvements in sleep parameters, marking a major milestone in Nexalin's strategy to expand its DIFS platform into high-prevalence neuropsychiatric conditions, with results expected to form the foundation for the company's planned FDA submission.
See More
Nexalin Advances Drug-Free Insomnia Treatment Clinical Trial
- Clinical Trial Design: Nexalin, in collaboration with Lindus Health, plans to recruit 150 participants in a triple-blinded, sham-controlled clinical trial in the U.S. to support its drug-free insomnia treatment submission to the FDA, marking a strategic expansion into neuropsychiatric indications.
- Technological Innovation: HALO™ Clarity leverages Nexalin's proprietary 15 mA DIFS™ technology to target deeper brain structures, offering a non-pharmacological treatment option that addresses the urgent needs of 30 million insomnia sufferers in the U.S., presenting significant market potential.
- Research Execution Model: The trial is structured as a fully decentralized study, allowing participants to complete treatments and assessments remotely through Nexalin's newly launched NeuroCare virtual clinic, aimed at increasing patient accessibility while reducing barriers to traditional clinical trial participation.
- Market Opportunity: The global insomnia therapeutics market represents a multi-billion-dollar annual opportunity, and as awareness and diagnosis increase, Nexalin's research not only enhances the market recognition of its technology but also potentially accelerates the regulatory approval process in a high-demand market.
See More
Nexalin Advances Pivotal Insomnia Clinical Trial
- Trial Overview: Nexalin is collaborating with Lindus Health to conduct a pivotal clinical trial in the U.S. aimed at enrolling at least 150 participants suffering from moderate to severe insomnia, with a randomized, triple-blinded, sham-controlled design that includes a four-week treatment period followed by a four-week follow-up to assess response durability.
- Remote Treatment Innovation: The trial is structured as fully decentralized, allowing participants to complete treatments and assessments remotely through Nexalin's newly launched NeuroCare virtual clinic and advanced Electronic Data Capture system, thereby eliminating traditional site visit requirements and expanding access to a broader patient population.
- FDA Submission Support: This pivotal study is designed to support Nexalin's planned de novo insomnia submission to the U.S. FDA, representing a key milestone in the company's global strategy to expand its Deep Intracranial Frequency Stimulation platform into high-prevalence neuropsychiatric indications, further validating the broader potential of its technology.
- Market Positioning: CEO Mark White emphasized that successful execution of this study will position Nexalin for regulatory clearance in a high-demand market, as insomnia affects approximately 30 million adults in the U.S., with the global insomnia therapeutics market representing a multi-billion-dollar annual opportunity that continues to grow with increasing awareness and diagnosis.
See More
Nexalin and First Phosphate to Feature on Bloomberg TV
- Nexalin Technology Innovation: Nexalin's CEO Mark White discussed the Gen-2 SYNC device on Bloomberg TV, which utilizes a 15 milliamp waveform to penetrate deep brain structures linked to depression and insomnia, potentially enhancing the effectiveness of mental health treatments and increasing the company's market share in the global mental health sector.
- International Regulatory Expansion: Nexalin is expanding its international regulatory clearances and implementing an FDA De Novo clinical strategy, indicating a strategic focus on the U.S. market, which will likely strengthen its position through a scalable device-plus-recurring-revenue model.
- First Phosphate Market Positioning: First Phosphate's founder John Passalacqua emphasized the company's goal to become a leading North American supplier of high-purity phosphate for the lithium iron phosphate (LFP) battery market, which is expected to benefit from the rapidly growing energy storage and electric mobility sectors.
- Vertical Integration Strategy: First Phosphate has successfully completed production and commercial performance testing of LFP battery cells made with North American-sourced critical minerals, showcasing its mine-to-market vertical integration strategy, which is anticipated to enhance its competitiveness within the battery value chain.
See More
Nexalin Launches AI-Designed Virtual Clinic Platform NeuroCare®
- Virtual Clinic Launch: Nexalin, in collaboration with UC San Diego, has launched the NeuroCare® virtual clinic platform aimed at enhancing patient access to treatments for Alzheimer's, mood disorders, and PTSD, which is expected to significantly reduce healthcare costs and improve long-term patient outcomes.
- Device Integration: The integration of the new Gen-3 HALO™ headset with the NeuroCare platform allows patients to receive Deep Intracranial Frequency Stimulation (DIFS™) treatment at home, enhancing privacy and convenience while providing physicians with real-time monitoring tools to optimize patient quality of life.
- Innovative Business Model: The NeuroCare platform operates on a subscription-based model, aiming to transition Nexalin from device sales to long-term patient retention and data-driven revenue growth, marking a significant strategic shift for the company.
- Market Expansion Potential: Nexalin plans to leverage the initial deployment alongside UC San Diego's clinical infrastructure to drive global expansion of its digital health ecosystem, which is expected to lay the foundation for sustainable growth in the global market and reinforce its leadership position in mental health.
See More
Nexalin Technology Reinforces Leadership in Non-Invasive Brain Stimulation
- Research Validation: Multiple independent peer-reviewed studies confirm that Nexalin's Deep Intracranial Frequency Stimulation (DIFS) technology can modulate deep brain structures associated with mood and cognition, showcasing its leadership in non-invasive brain stimulation.
- Neuroimaging Evidence: Peer-reviewed neuroimaging research indicates measurable changes in brain activity following treatment, further supporting the efficacy of DIFS technology in mental health treatment.
- Clinical Relevance: Research highlights the potential of DIFS to address psychiatric and neurological conditions where conventional therapies may fall short, meeting the needs of millions of patients worldwide seeking more effective treatments.
- Non-Invasive Advantage: Nexalin's DIFS technology offers a safer and more accessible treatment option without the need for surgery, implants, or pharmaceuticals, aligning with modern healthcare's pursuit of innovation and effectiveness.
See More
Nexalin Advances HALO Clarity Clinical Trial for Insomnia Treatment
- Clinical Trial Launch: Nexalin Technology is advancing its HALO Clarity program by initiating a pivotal clinical trial aimed at supporting a de novo submission to the U.S. FDA for moderate to severe insomnia treatment, which is expected to provide a competitive edge in the multi-billion-dollar insomnia market.
- Technological Innovation: The company positions its non-drug Deep Intracranial Frequency Stimulation (DIFS) technology as a potential alternative to address insomnia affecting approximately 30 million adults in the U.S., particularly as many patients express dissatisfaction with current treatment options due to concerns about dependency and tolerability.
- Trial Design: The HALO Clarity study is a randomized, triple-blinded, sham-controlled trial designed to enroll at least 150 adults, utilizing a fully decentralized model that allows participants to complete treatments and assessments remotely through Nexalin's NeuroCare virtual clinic, thereby broadening patient access.
- Strategic Implications: This trial builds on previously published clinical data demonstrating significant improvements in sleep parameters, marking a major milestone in Nexalin's strategy to expand its DIFS platform into high-prevalence neuropsychiatric conditions, with results expected to form the foundation for the company's planned FDA submission.
See More
Nexalin Advances Drug-Free Insomnia Treatment Clinical Trial
- Clinical Trial Design: Nexalin, in collaboration with Lindus Health, plans to recruit 150 participants in a triple-blinded, sham-controlled clinical trial in the U.S. to support its drug-free insomnia treatment submission to the FDA, marking a strategic expansion into neuropsychiatric indications.
- Technological Innovation: HALO™ Clarity leverages Nexalin's proprietary 15 mA DIFS™ technology to target deeper brain structures, offering a non-pharmacological treatment option that addresses the urgent needs of 30 million insomnia sufferers in the U.S., presenting significant market potential.
- Research Execution Model: The trial is structured as a fully decentralized study, allowing participants to complete treatments and assessments remotely through Nexalin's newly launched NeuroCare virtual clinic, aimed at increasing patient accessibility while reducing barriers to traditional clinical trial participation.
- Market Opportunity: The global insomnia therapeutics market represents a multi-billion-dollar annual opportunity, and as awareness and diagnosis increase, Nexalin's research not only enhances the market recognition of its technology but also potentially accelerates the regulatory approval process in a high-demand market.
See More
Nexalin Advances Pivotal Insomnia Clinical Trial
- Trial Overview: Nexalin is collaborating with Lindus Health to conduct a pivotal clinical trial in the U.S. aimed at enrolling at least 150 participants suffering from moderate to severe insomnia, with a randomized, triple-blinded, sham-controlled design that includes a four-week treatment period followed by a four-week follow-up to assess response durability.
- Remote Treatment Innovation: The trial is structured as fully decentralized, allowing participants to complete treatments and assessments remotely through Nexalin's newly launched NeuroCare virtual clinic and advanced Electronic Data Capture system, thereby eliminating traditional site visit requirements and expanding access to a broader patient population.
- FDA Submission Support: This pivotal study is designed to support Nexalin's planned de novo insomnia submission to the U.S. FDA, representing a key milestone in the company's global strategy to expand its Deep Intracranial Frequency Stimulation platform into high-prevalence neuropsychiatric indications, further validating the broader potential of its technology.
- Market Positioning: CEO Mark White emphasized that successful execution of this study will position Nexalin for regulatory clearance in a high-demand market, as insomnia affects approximately 30 million adults in the U.S., with the global insomnia therapeutics market representing a multi-billion-dollar annual opportunity that continues to grow with increasing awareness and diagnosis.
See More
Nexalin and First Phosphate to Feature on Bloomberg TV
- Nexalin Technology Innovation: Nexalin's CEO Mark White discussed the Gen-2 SYNC device on Bloomberg TV, which utilizes a 15 milliamp waveform to penetrate deep brain structures linked to depression and insomnia, potentially enhancing the effectiveness of mental health treatments and increasing the company's market share in the global mental health sector.
- International Regulatory Expansion: Nexalin is expanding its international regulatory clearances and implementing an FDA De Novo clinical strategy, indicating a strategic focus on the U.S. market, which will likely strengthen its position through a scalable device-plus-recurring-revenue model.
- First Phosphate Market Positioning: First Phosphate's founder John Passalacqua emphasized the company's goal to become a leading North American supplier of high-purity phosphate for the lithium iron phosphate (LFP) battery market, which is expected to benefit from the rapidly growing energy storage and electric mobility sectors.
- Vertical Integration Strategy: First Phosphate has successfully completed production and commercial performance testing of LFP battery cells made with North American-sourced critical minerals, showcasing its mine-to-market vertical integration strategy, which is anticipated to enhance its competitiveness within the battery value chain.
See More
Nexalin Launches AI-Designed Virtual Clinic Platform NeuroCare®
- Virtual Clinic Launch: Nexalin, in collaboration with UC San Diego, has launched the NeuroCare® virtual clinic platform aimed at enhancing patient access to treatments for Alzheimer's, mood disorders, and PTSD, which is expected to significantly reduce healthcare costs and improve long-term patient outcomes.
- Device Integration: The integration of the new Gen-3 HALO™ headset with the NeuroCare platform allows patients to receive Deep Intracranial Frequency Stimulation (DIFS™) treatment at home, enhancing privacy and convenience while providing physicians with real-time monitoring tools to optimize patient quality of life.
- Innovative Business Model: The NeuroCare platform operates on a subscription-based model, aiming to transition Nexalin from device sales to long-term patient retention and data-driven revenue growth, marking a significant strategic shift for the company.
- Market Expansion Potential: Nexalin plans to leverage the initial deployment alongside UC San Diego's clinical infrastructure to drive global expansion of its digital health ecosystem, which is expected to lay the foundation for sustainable growth in the global market and reinforce its leadership position in mental health.
See More
Nexalin Technology Reinforces Leadership in Non-Invasive Brain Stimulation
- Research Validation: Multiple independent peer-reviewed studies confirm that Nexalin's Deep Intracranial Frequency Stimulation (DIFS) technology can modulate deep brain structures associated with mood and cognition, showcasing its leadership in non-invasive brain stimulation.
- Neuroimaging Evidence: Peer-reviewed neuroimaging research indicates measurable changes in brain activity following treatment, further supporting the efficacy of DIFS technology in mental health treatment.
- Clinical Relevance: Research highlights the potential of DIFS to address psychiatric and neurological conditions where conventional therapies may fall short, meeting the needs of millions of patients worldwide seeking more effective treatments.
- Non-Invasive Advantage: Nexalin's DIFS technology offers a safer and more accessible treatment option without the need for surgery, implants, or pharmaceuticals, aligning with modern healthcare's pursuit of innovation and effectiveness.
See More
